B-Raf mutant inhibitors (Shanghai Institute of Materia Medica/Central South University/Nanjing University/The Wistar Institute)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameB-Raf mutant inhibitors (Shanghai Institute of Materia Medica/Central South University/Nanjing University/The Wistar Institute)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitors
TargetsSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Wistar Institute Of Anatomy And BiologyCentral South UniversityNanjing University +[4] 
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A